Perrigo plans spin-off of Israel biz
This article was originally published in The Rose Sheet
Executive Summary
Private label manufacturer Perrigo is looking for a buyer for its Israel consumer products segment, firm announces during a fiscal 2009 third quarter earnings call May 7. The division, which includes Careline beauty brands, has been deemed a "non-core" business for the OTC drug and nutritional products manufacturer. Israel consumer products segment experienced sales decline of 22% to $18 mil. in the third quarter and gross profit was $5 mil., down from $8 mil. in the prior-year quarter, company notes. "It is actually a business that has a good history, has got some good brands...So we do expect to see interest in the business," says CEO and Chairman Joseph C. Papa
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.